Isabelle C. VAN Gelder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabelle C. VAN Gelder has a total of 338 co-authors. Here are the top co-authors by number of shared publications:
- Dirk J. van Veldhuisen
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands
6 shared publications Harry J.G.M. Crijns
6 shared publicationsM Rienstra
University Medical Center Groningen, Cardiology, Groningen, Netherlands
5 shared publicationsAnton E. Tuinenburg
Department of Cardiology, Thoraxcenter, Groningen
4 shared publicationsB Geelhoed
University Medical Center Groningen, Cardiology, Groningen, Netherlands
4 shared publications- H. L. Hillege
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands
4 shared publications
Latest Publications
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2294Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
Introduction: Atrial fibrillation (AF) is a progressive disease. Many risk factors have been described for AF.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2294Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
Introduction: Atrial fibrillation (AF) is a progressive disease. Many risk factors have been described for AF.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i7
54Treating underlying conditions improves quality of life in patients with persistent atrial fibrillation and heart failure - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i7
54Treating underlying conditions improves quality of life in patients with persistent atrial fibrillation and heart failure - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i190
1002Significance of type of baseline AF and type of recurrence in relation to outcome of hybrid AF ablation
Funding Acknowledgements: Grant support to the institution from Medtronic and Atricure
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i190
1002Significance of type of baseline AF and type of recurrence in relation to outcome of hybrid AF ablation
Funding Acknowledgements: Grant support to the institution from Medtronic and Atricure
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i49
P320End-systolic septum strain: a multi-modality strain parameter that accurately predicts cardiac resynchronization therapy response
Objectives: This study aims to compare predictive performance of different strain parameters and evaluate results per imaging modality to predict cardiac resynchronization therapy (CRT) response.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i49
P320End-systolic septum strain: a multi-modality strain parameter that accurately predicts cardiac resynchronization therapy response
Objectives: This study aims to compare predictive performance of different strain parameters and evaluate results per imaging modality to predict cardiac resynchronization therapy (CRT) response.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i226-i227
P1175Determinants of progression of persistent to permanent atrial fibrillation - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i226-i227
P1175Determinants of progression of persistent to permanent atrial fibrillation - data from the RACE 3 study
On behalf of: RACE 3 study group
- Open Access
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Poster Session 1: Ablation of SVT and VT
Introduction: Catheter ablation has evolved as a possible curative treatment modality for late post-operative atrial tachyarrhythmias (AT). The goal of this study was to evaluate the incidence of AT after catheter ablation of late post-operative AT during long-term follow-up in a large cohort of patients with predominantly complex congenital heart defects. In addition, the complexity of the congenital heart defects was correlated with characteristics of late post-operative AT and both the procedural and long-term outcome of ablative therapy.
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Open AccessPoster Session 1: Ablation of SVT and VT
Introduction: Catheter ablation has evolved as a possible curative treatment modality for late post-operative atrial tachyarrhythmias (AT). The goal of this study was to evaluate the incidence of AT after catheter ablation of late post-operative AT during long-term follow-up in a large cohort of patients with predominantly complex congenital heart defects. In addition, the complexity of the congenital heart defects was correlated with characteristics of late post-operative AT and both the procedural and long-term outcome of ablative therapy.
- Open Access
- 24 January 2005
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 5 (1) , 3
Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation
Background: Persistent atrial fibrillation (AF) is difficult to treat. In the absence of class I or III antiarrhythmic drugs sinus rhythm is maintained in only 30% of patients during the first year after electrical cardioversion (ECV). One of the remodeling processes induced by AF is fibrosis, which relates to inducibility and maintenance of AF. The renin-angiotensin system may play a important role in this. The aim of this study was to investigate the role of angiotensin-converting enzyme (ACE) inhibitor use on efficacy of ECV, and occurrence of subacute recurrences. Methods: One hundred-seven consecutive patients with persistent AF underwent ECV. In twenty-eight (26%) patients ACE inhibitors had been started before initiation of the present episode of AF ('pre-treated' patients). Results: ECV was successful in 96% of patients who were on ACE inhibitors before start of the present episode of AF compared to 80% of the patients not pre-treated (p = 0.04). After 1 month of follow-up 49% of the pre-treated patients and 50% of those not pre-treated with ACE inhibition were still in sinus rhythm (p=ns). Multivariate analysis showed that pre-treatment with ACE inhibitors and a smaller left atrial size were independent predictors of successful ECV (OR = 5.8, C.I. 1.3–26.1, and OR = 5.6, C.I. 1.2–25.3, respectively). Conclusions: Pre-treatment with ACE inhibitors may improve acute success of ECV but does not prevend AF recurrences.
- 24 January 2005
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 5 (1) , 3
Open AccessPretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation
Background: Persistent atrial fibrillation (AF) is difficult to treat. In the absence of class I or III antiarrhythmic drugs sinus rhythm is maintained in only 30% of patients during the first year after electrical cardioversion (ECV). One of the remodeling processes induced by AF is fibrosis, which relates to inducibility and maintenance of AF. The renin-angiotensin system may play a important role in this. The aim of this study was to investigate the role of angiotensin-converting enzyme (ACE) inhibitor use on efficacy of ECV, and occurrence of subacute recurrences. Methods: One hundred-seven consecutive patients with persistent AF underwent ECV. In twenty-eight (26%) patients ACE inhibitors had been started before initiation of the present episode of AF ('pre-treated' patients). Results: ECV was successful in 96% of patients who were on ACE inhibitors before start of the present episode of AF compared to 80% of the patients not pre-treated (p = 0.04). After 1 month of follow-up 49% of the pre-treated patients and 50% of those not pre-treated with ACE inhibition were still in sinus rhythm (p=ns). Multivariate analysis showed that pre-treatment with ACE inhibitors and a smaller left atrial size were independent predictors of successful ECV (OR = 5.8, C.I. 1.3–26.1, and OR = 5.6, C.I. 1.2–25.3, respectively). Conclusions: Pre-treatment with ACE inhibitors may improve acute success of ECV but does not prevend AF recurrences.
- 11 September 2004
- Vol. 148 (37) , 1809-15
[Cardiac rehabilitation in patients with a congenital heart disease, an implantable cardioverter defibrillator or chronic heart failure].
Cardiac rehabilitation is no longer just used to treat patients after the manifestation of a coronary artery disease such as a myocardial infarct, after a PTCA or after a coronary bypass operation. Patients with a congenital heart disease, patients who have received an implantable cardioverter defibrillator (ICD) and patients with stable chronic heart failure are also suitable candidates for a multidisciplinary cardiac rehabilitation programme. The new Dutch guidelines for cardiac rehabilitation, published in 2004, can be helpful in identifying potential candidates for a programme. Physical training is often a component of the treatment, but psycho-social counselling and education targeted at reducing anxiety and uncertainty, accepting the heart disease and learning to cope with it, can be just as important as those aspects targeted at improving the physical condition. Cardiac rehabilitation that includes physical training is safe for patients with congenital heart disease, for patients who have undergone an ICD implantation and for patients with stable chronic heart failure, as long as the pretraining exercise test is given a guiding role in selecting the appropriate physical work load. Patients with stable chronic heart failure should continue their physical training in order to maintain its beneficial physical and psychological effects.
- 11 September 2004
- Vol. 148 (37) , 1809-15
[Cardiac rehabilitation in patients with a congenital heart disease, an implantable cardioverter defibrillator or chronic heart failure].
Cardiac rehabilitation is no longer just used to treat patients after the manifestation of a coronary artery disease such as a myocardial infarct, after a PTCA or after a coronary bypass operation. Patients with a congenital heart disease, patients who have received an implantable cardioverter defibrillator (ICD) and patients with stable chronic heart failure are also suitable candidates for a multidisciplinary cardiac rehabilitation programme. The new Dutch guidelines for cardiac rehabilitation, published in 2004, can be helpful in identifying potential candidates for a programme. Physical training is often a component of the treatment, but psycho-social counselling and education targeted at reducing anxiety and uncertainty, accepting the heart disease and learning to cope with it, can be just as important as those aspects targeted at improving the physical condition. Cardiac rehabilitation that includes physical training is safe for patients with congenital heart disease, for patients who have undergone an ICD implantation and for patients with stable chronic heart failure, as long as the pretraining exercise test is given a guiding role in selecting the appropriate physical work load. Patients with stable chronic heart failure should continue their physical training in order to maintain its beneficial physical and psychological effects.
- 1 August 2004
- Vol. 12, 321-322
Differences in guidelines for the diagnostic evaluation and treatment of atrial fibrillation.
- 1 August 2004
- Vol. 12, 321-322
Differences in guidelines for the diagnostic evaluation and treatment of atrial fibrillation.
- Top Cited Papers
- 5 December 2002
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (23) , 1834-1840
A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation
Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation.
- 5 December 2002
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (23) , 1834-1840
Top Cited PapersA Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation
Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation.